CLDX
Celldex Therapeutics, Inc. NASDAQ Listed May 15, 1986$33.31
After hrs
$33.98
+1.98%
Mkt Cap $2.2B
52w Low $18.00
86.1% of range
52w High $35.79
50d MA $31.70
200d MA $26.73
P/E (TTM)
-8.3x
EV/EBITDA
-7.0x
P/B
4.1x
Debt/Equity
0.0x
ROE
-49.1%
P/FCF
-8.5x
RSI (14)
—
ATR (14)
—
Beta
1.20
50d MA
$31.70
200d MA
$26.73
Avg Volume
1.0M
About
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the rece…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -1.00 | -1.22 | -22.0% | 30.82 | -2.5% | -0.6% | -2.4% | -2.7% | -6.1% | -4.2% | — |
| Nov 10, 2025 | AMC | -0.88 | -1.01 | -14.8% | 22.67 | -1.8% | +7.5% | +7.0% | +4.6% | +12.7% | +14.7% | — |
| Aug 7, 2025 | AMC | -0.86 | -0.85 | +1.2% | 21.21 | -4.4% | -2.6% | -5.7% | +12.2% | +17.8% | +17.6% | — |
| May 8, 2025 | AMC | -0.75 | -0.81 | -8.0% | 19.52 | -6.8% | -6.1% | +3.4% | +0.5% | -3.0% | +3.0% | — |
| Feb 27, 2025 | AMC | -0.73 | -0.71 | +2.7% | 20.31 | -2.0% | +1.3% | -4.7% | -1.5% | +3.9% | +5.0% | — |
| Nov 6, 2024 | AMC | -0.69 | -0.64 | +7.2% | 27.63 | +1.3% | -4.2% | -5.1% | -5.1% | -2.2% | -2.9% | — |
| Aug 8, 2024 | AMC | -0.59 | -0.54 | +8.5% | 32.71 | +0.4% | +0.6% | +2.3% | +1.7% | -1.2% | +1.2% | — |
| May 6, 2024 | AMC | -0.67 | -0.56 | +16.4% | 41.65 | -1.4% | +1.3% | -1.1% | -1.4% | -4.2% | -3.7% | — |
| Feb 26, 2024 | AMC | -0.76 | -0.57 | +25.0% | 48.23 | +1.9% | +5.8% | +6.5% | -0.4% | +7.6% | +5.1% | — |
| Nov 2, 2023 | AMC | -0.67 | -0.81 | -20.9% | 24.01 | +5.8% | +8.2% | +22.2% | +20.9% | +10.4% | +7.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Barclays | Upgrade | Underweight → Overweight | — | $34.55 | $35.79 | +3.6% | -0.5% | -0.9% | -1.0% | -2.9% | -3.6% |
| Mar 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.09 | $29.94 | -0.5% | -0.3% | -3.8% | -1.8% | -2.4% | -2.2% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $30.82 | $30.05 | -2.5% | -0.6% | -2.4% | -2.7% | -6.1% | -4.2% |
| Dec 17 | Barclays | Maintains | Underweight → Underweight | — | $26.68 | $26.59 | -0.3% | -3.4% | -5.2% | -4.0% | +2.2% | -0.4% |
| Nov 11 | Barclays | Maintains | Underweight → Underweight | — | $22.67 | $22.26 | -1.8% | +7.5% | +7.0% | +4.6% | +12.7% | +14.7% |
| Sep 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.58 | $24.32 | -1.1% | -0.5% | +5.5% | +0.1% | +1.1% | -1.4% |
| Aug 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Aug 20 | Citigroup | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
| Aug 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | -8.3% | -6.5% | -8.7% | -9.5% |
Recent Filings
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
CLDX entered into an underwriting agreement with Leerink Partners, likely signaling an upcoming secondary offering that could dilute existing shareholders but provide needed capital for operations or acquisitions.
Apr 2
8-K
Celldex Therapeutics, Inc -- 8-K Filing
Celldex Therapeutics' barzolvolimab advanced efficacy data and ahead-of-schedule Phase 3 enrollment completion in chronic spontaneous urticaria suggest positive momentum that could support future regulatory approvals and revenue growth.
Feb 25
Data updated apr 25, 2026 1:37am
· Source: massive.com